Indivior (INDV) Competitors $9.11 -0.33 (-3.50%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$9.20 +0.09 (+0.99%) As of 04/15/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INDV vs. BPMC, SRPT, TLX, AXSM, KRYS, NUVL, GRFS, ELAN, VRNA, and ADMAShould you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Indivior vs. Blueprint Medicines Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Axsome Therapeutics Krystal Biotech Nuvalent Grifols Elanco Animal Health Verona Pharma ADMA Biologics Blueprint Medicines (NASDAQ:BPMC) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability. Do institutionals and insiders believe in BPMC or INDV? 60.3% of Indivior shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is BPMC or INDV more profitable? Indivior has a net margin of -3.96% compared to Blueprint Medicines' net margin of -13.19%. Blueprint Medicines' return on equity of -77.49% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-13.19% -77.49% -20.84% Indivior -3.96%-241.73%15.09% Do analysts recommend BPMC or INDV? Blueprint Medicines presently has a consensus price target of $124.95, indicating a potential upside of 53.41%. Indivior has a consensus price target of $15.00, indicating a potential upside of 64.65%. Given Indivior's stronger consensus rating and higher probable upside, analysts clearly believe Indivior is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 1 Sell rating(s) 6 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.70Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media refer more to BPMC or INDV? In the previous week, Blueprint Medicines had 6 more articles in the media than Indivior. MarketBeat recorded 11 mentions for Blueprint Medicines and 5 mentions for Indivior. Indivior's average media sentiment score of 1.58 beat Blueprint Medicines' score of 1.05 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Indivior 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk and volatility, BPMC or INDV? Blueprint Medicines has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Does the MarketBeat Community believe in BPMC or INDV? Blueprint Medicines received 539 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 68.15% of users gave Blueprint Medicines an outperform vote. CompanyUnderperformOutperformBlueprint MedicinesOutperform Votes55068.15% Underperform Votes25731.85% IndiviorOutperform Votes11100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, BPMC or INDV? Indivior has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M10.23-$67.09M-$1.08-75.42Indivior$1.19B1.06$2M-$0.35-26.03 SummaryIndivior beats Blueprint Medicines on 12 of the 18 factors compared between the two stocks. Remove Ads Get Indivior News Delivered to You Automatically Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDV vs. The Competition Export to ExcelMetricIndiviorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.26B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-26.036.7921.7317.82Price / Sales1.06225.96379.2094.61Price / Cash4.9465.6738.1534.64Price / BookN/A5.866.464.00Net Income$2M$141.86M$3.20B$247.23M7 Day Performance-5.99%4.50%2.86%1.45%1 Month Performance-5.89%-12.65%-8.55%-6.24%1 Year Performance-53.02%-11.06%10.47%0.60% Indivior Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDVIndivior3.7751 of 5 stars$9.11-3.5%$15.00+64.7%-53.9%$1.26B$1.19B-26.031,164Short Interest ↓Positive NewsBPMCBlueprint Medicines2.6341 of 5 stars$80.20-1.8%$124.95+55.8%-4.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6725 of 5 stars$52.40-3.7%$163.18+211.4%-54.0%$5.08B$1.90B41.92840Short Interest ↑Gap DownHigh Trading VolumeTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$14.25+4.7%$22.00+54.4%N/A$4.81B$783.21M0.00N/AAXSMAxsome Therapeutics4.5817 of 5 stars$98.50-0.4%$169.80+72.4%+52.2%$4.80B$385.69M-16.44380Analyst RevisionKRYSKrystal Biotech4.6447 of 5 stars$166.01-3.1%$220.00+32.5%-0.4%$4.78B$290.52M55.52210NUVLNuvalent1.8517 of 5 stars$64.68-1.6%$113.44+75.4%+8.4%$4.63BN/A-18.6440Positive NewsGRFSGrifols3.0949 of 5 stars$6.55-1.5%N/A+6.9%$4.50B$7.21B5.6026,300Gap UpELANElanco Animal Health4.3408 of 5 stars$8.95-2.2%$15.17+69.6%-40.6%$4.44B$4.44B22.369,800Analyst ForecastGap DownVRNAVerona Pharma2.2461 of 5 stars$54.30+0.7%$69.14+27.3%+270.1%$4.39B$42.28M-28.2830Positive NewsGap UpHigh Trading VolumeADMAADMA Biologics1.8854 of 5 stars$18.40+2.2%$22.50+22.3%+270.4%$4.35B$426.45M65.71530Options VolumeNews CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies BPMC Alternatives SRPT Alternatives TLX Alternatives AXSM Alternatives KRYS Alternatives NUVL Alternatives GRFS Alternatives ELAN Alternatives VRNA Alternatives ADMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INDV Stock Free INDV Stock Alerts